Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
In the U.S., ∼21 × 106 individuals have type 2 diabetes, and twice as many have impaired glucose tolerance (IGT). Approximately 40–50% of individuals with IGT will progress to type 2 diabetes over their lifetime. Therefore, treatment of high-risk individuals with IGT to prevent type 2 diabetes has important medical, economic, social, and human implications. Weight loss, although effective in reducing the conversion of IGT to type 2 diabetes, is difficult to achieve and maintain. Moreover, 40–50% of IGT subjects progress to type 2 diabetes despite successful weight reduction. In contrast, pharmacological treatment of IGT with oral antidiabetic agents that improve insulin sensitivity and preserve β-cell function—the characteristic pathophysiological abnormalities present in IGT and type 2 diabetes—uniformly have been shown to prevent progression of IGT to type 2 diabetes. The most consistent results have been observed with the thiazolidinediones (Troglitazone in the Prevention of Diabetes [TRIPOD], Pioglitazone in the Prevention of Diabetes [PIPOD], Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication [DREAM], and Actos Now for the Prevention of Diabetes [ACT NOW]), with a 50–70% reduction in IGT conversion to diabetes. Metformin in the U.S. Diabetes Prevention Program (DPP) reduced the development of type 2 diabetes by 31% and has been recommended by the American Diabetes Association (ADA) for treating high-risk individuals with IGT. The glucagon-like peptide-1 analogs, which augment insulin secretion, preserve β-cell function, and promote weight loss, also would be expected to be efficacious in preventing the progression of IGT to type 2 diabetes. Because individuals in the upper tertile of IGT are maximally/near-maximally insulin resistant, have lost 70–80% of their β-cell function, and have an ∼10% incidence of diabetic retinopathy, pharmacological intervention, in combination with diet plus exercise, should be instituted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“Four large prospective studies demonstrated that a treatment regimen using diet plus exercise reduces IGT progression to type 2 diabetes (17,18,33,34).”
Background10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“Results from the Diabetes Control and Complications Trial (3) (8a), UK Prospective Diabetes Study (4,5), and other trials (9a) have established hyperglycemia as the major risk factor for microvascular and, to a lesser extent, macrovascular (6) (10a,11a) complications.”
BackgroundEconomic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Self-citationGlycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
DeFronzo, R. A., & Tripathy, D. (2009) · Diabetes Care · doi:10.2337/dc09-s302 · Cited by 2,102 · cited 3×
“, insulin resistance or b-cell dysfunction, represents the primary abnormality (11,22) (74a–78a).”
BackgroundSelf-citationRamachandran, A., Snehalatha, C., Mary, S., Mukesh, B., Bhaskar, A. D., Vijay, V., & Indian Diabetes Prevention Programme (IDPP) (2006) · Diabetologia · doi:10.1007/s00125-005-0097-z · Cited by 1,881
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
(2006) · The Lancet · doi:10.1016/s0140-6736(06)69420-8 · Cited by 1,706 · cited 4×
“In DREAM, rosiglitazone reduced IGT conversion to type 2 diabetes by 62% (20) (Fig.”
BackgroundResultInfluentialReduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes
The Look AHEAD Research Group (2007) · Diabetes Care · doi:10.2337/dc07-0048 · Cited by 1,522 · cited 1×
“The Look AHEAD trial (36), which, like DPP, demonstrated impressive weight loss at year 1, was also followed by significant weight regain over the subsequent 3 years despite continued intensive intervention and follow-up (Supplementary Table 1).”
MethodImpaired Fasting Glucose and Impaired Glucose Tolerance
Nathan, D. M., Davidson, M. B., DeFronzo, R. A., Heine, R. J., Henry, R. R., Pratley, R., & Zinman, B. (2007) · Diabetes Care · doi:10.2337/dc07-9920 · Cited by 1,396 · cited 6×
“Because impaired b-cell function and insulin resistance are characteristic features of IGT/IFG, interventions that preserve/augment b-cell function and ameliorate insulin resistance are most likely to prevent/slow IGT progression to diabetes.”
BackgroundInfluentialSelf-citationBuchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H. N., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2796 · Cited by 1,339
Economic costs of diabetes in the U.S. in 2007
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-9017 · Cited by 1,323
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · cited 1×
“Once-daily liraglutide also reduces body weight and decreases IGT conversion to type 2 diabetes in obese nondiabetic subjects (50).”
BackgroundEriksson, K. F., & Lindg�rde, F. (1991) · Diabetologia · doi:10.1007/bf00400196 · Cited by 1,092
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Hodis, H. N., Kitabchi, A. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010949 · Cited by 766 · cited 9×
“Although the pioglitazone dose in ACT NOWwas 45 mg/day, lower doses (15–30mg/day) improve insulin sensitivity and insulin secretion (160a) in type 2 diabetes and were effective in decreasing IGT conversion to type 2 diabetes and in reverting IGT to NGT in ACT NOW (21).”
BackgroundInfluentialSelf-citationAbdul-Ghani, M. A., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes Care · doi:10.2337/dc05-2179 · Cited by 744
Self-citationKlonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · cited 1×
“Long-term (3 years) exenatide treatment is associated with maintained glycemic control, progressive weight loss, and improved b-cell function (48).”
BackgroundDIABETES INCIDENCE IN PIMA INDIANS: CONTRIBUTIONS OF OBESITY AND PARENTAL DIABETES1
KNOWLER, W. C., PETTITT, D. J., SAVAGE, P. J., & BENNETT, P. H. (1981) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113079 · Cited by 561
Ferrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1133 · Cited by 540 · cited 2×
“In two large studies— the San Antonio Metabolism Study (31) (15a) and the Veterans Administration”
BackgroundSelf-citationAbdul-Ghani, M. A., Jenkinson, C. P., Richardson, D. K., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes · doi:10.2337/db05-1200 · Cited by 500 · cited 12×
“Because impaired b-cell function and insulin resistance are characteristic features of IGT/IFG, interventions that preserve/augment b-cell function and ameliorate insulin resistance are most likely to prevent/slow IGT progression to diabetes.”
BackgroundMethodInfluentialSelf-citationPrevention of Type 2 Diabetes With Troglitazone in the Diabetes Prevention Program
The Diabetes Prevention Program Research Group* (2005) · Diabetes · doi:10.2337/diabetes.54.4.1150 · Cited by 474
The natural history of impaired glucose tolerance in the Pima Indians
Saad, M. F., Knowler, W. C., Pettitt, D. J., Nelson, R. G., Mott, D. M., & Bennett, P. H. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812083192302 · Cited by 413 · cited 2×
“Hyperinsulinemia, which reflects underlying insulin resistance (9–11,24–26) (73a,77a,91a, 92a), is common in populations with a high prevalence of type 2 diabetes and predicts the development of IGT and type 2 diabetes in Caucasians (31a,85a, 93a), Mexican Americans (23a,33a,57a, 94a), Naurians (59a), Japanese America…”
BackgroundBunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388 · cited 1×
“(49) in type 2 diabetes strongly argues against an effect of GLP-1 to increase b-cell mass in humans, since discontinuation of exenatide for 1 month was associated with return of b-cell function to pretreatment levels.”
BackgroundDiabetes Prevention Program Research Group (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02043.x · Cited by 363
Quality of Diabetes Care in U.S. Academic Medical Centers
Grant, R. W., Buse, J. B., Meigs, J. B., & for the University HealthSystem Consortium (UHC) Diabetes Benchmarking Project Team (2005) · Diabetes Care · doi:10.2337/diacare.28.2.337 · Cited by 311
Kawamori, R., Tajima, N., Iwamoto, Y., Kashiwagi, A., Shimamoto, K., & Kaku, K. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60222-1 · Cited by 303
Lifestyle Intervention for Prevention of Type 2 Diabetes in Primary Health Care
Saaristo, T., Moilanen, L., Korpi-Hyövälti, E., Vanhala, M., Saltevo, J., Niskanen, L., Jokelainen, J., Peltonen, M., Oksa, H., Tuomilehto, J., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0410 · Cited by 302 · cited 1×
“In a recent community study in Finland (37), 2,797 high-risk individuals were enrolled in a diabetes prevention program designed to achieve 5–7% body weight loss.”
BackgroundGulli, G., Ferrannini, E., Stern, M., Haffner, S., & DeFronzo, R. A. (1992) · Diabetes · doi:10.2337/diab.41.12.1575 · Cited by 283
Self-citationZinman, B., Harris, S. B., Neuman, J., Gerstein, H. C., Retnakaran, R. R., Raboud, J., Qi, Y., & Hanley, A. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60746-5 · Cited by 235
Glucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture, 2005
Holst, J. J. (2006) · Diabetologia · doi:10.1007/s00125-005-0107-1 · Cited by 228
Thiazolidinediones improve β-cell function in type 2 diabetic patients
Gastaldelli, A., Ferrannini, E., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00551.2006 · Cited by 200
Self-citationThe Diabetes Prevention Program Research Group, Venditti, E. M., Bray, G. A., Carrion-Petersen, M. L., Delahanty, L. M., Edelstein, S. L., Hamman, R. F., Hoskin, M. A., Knowler, W. C., & Ma., Y. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.134 · Cited by 93 · cited 1×
“DPP, weight loss was largely regained after the DPP ended, despite initiation of the HELP program (35) (Fig.”
Cited by
Upregulated NLRP3 Inflammasome Activation in Patients With Type 2 Diabetes
Lee, H.-M., Kim, J.-J., Kim, H. J., Shong, M., Ku, B. J., & Jo, E.-K. (2013) · Diabetes · doi:10.2337/db12-0420 · Cited by 734
Colca, J. R., McDonald, W. G., Cavey, G. S., Cole, S. L., Holewa, D. D., Brightwell-Conrad, A. S., Wolfe, C. L., Wheeler, J. S., Coulter, K. R., Kilkuskie, P. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061551 · Cited by 171
“of pre-diabetic patients to frank disease [2,3].”
Novel views on new-onset diabetes after transplantation: development, prevention and treatment
Hecking, M., Werzowa, J., Haidinger, M., Horl, W. H., Pascual, J., Budde, K., Luan, F. L., Ojo, A., de Vries, A. P. J., Porrini, E., et al. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs583 · Cited by 120
An assessment by the Statin Diabetes Safety Task Force: 2014 update
Maki, K. C., Ridker, P. M., Brown, W. V., Grundy, S. M., & Sattar, N. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.02.012 · Cited by 119
Zhang, F., Tong, Y., Su, N., Li, Y., Tang, L., Huang, L., & Tong, N. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12198 · Cited by 59
Metadata
- Authors
- DeFronzo, R. A., & Abdul-Ghani, M.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-04-22
- Volume
- 34
- Issue
- Supplement_2
- Pages
- S202-S209
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2131419387
- Cited by
- 147
- References
- 37
- FWCI
- 15.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.